百奥赛图-B(02315)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02315 百奥赛图-B

未开盘 03-28 16:08:43

24.950

-0.250

-0.99%

最高25.350	最低24.900	成交量12.85万
今开25.250	昨收25.200	日振幅1.79%
总市值99.65亿	流通市值27.64亿	总股本3.99亿
成交额322.26万	换手率0.12%	流通股本1.11亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02315","market":"HK","secType":"STK","nameCN":"百奥赛图-B","latestPrice":24.95,"timestamp":1679990923015,"preClose":25.2,"halted":0,"volume":128500,"delay":0,"floatShares":110781920,"shares":399398420,"eps":-1.7172767,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.25,"latestTime":"03-28 16:08:43","open":25.25,"high":25.35,"low":24.9,"amount":3222550,"amplitude":0.017857,"askPrice":24.95,"askSize":500,"bidPrice":24.9,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":-1.7548344514133651,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1680053400000},"adr":0,"listingDate":1661961600000,"adjPreClose":25.2,"volumeRatio":0.949741,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02315","defaultTab":"news","newsList":[{"id":"2322888632","title":"百奥赛图-B(2315.HK)：“Biotech+CRO”稀缺质地，多重驱动未来可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2322888632","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2322888632?lang=zh_CN&edition=full","pubTime":"2023-03-28 09:33","pubTimestamp":1679967221,"startTime":"0","endTime":"0","summary":"百奥赛图已开始启动科创板辅导上市进程，有望成为下一家“A+H”两地上市的18A公司。","market":"hk","thumbnail":"https://img7.gelonghui.com/column/1.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/1.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/589523","is_publish_highlight":false},{"id":"2322542377","title":"快讯 | 百奥赛图：2022年收益5.34亿元；权益股东应占年内亏损6.02亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2322542377","media":"财经网","top":-1,"share":"https://www.laohu8.com/m/news/2322542377?lang=zh_CN&edition=full","pubTime":"2023-03-27 20:14","pubTimestamp":1679919260,"startTime":"0","endTime":"0","summary":"财经网医药讯 3月27日，百奥赛图发布2022年年报。2022年公司收益5.34亿元，同比增长50.6%；公司权益股东应占年内亏损6.02亿元，同比增长10.3%；报告期内，公司销售及营销开支约为5020万元，同比增加19.5%，该增加主要是由于薪金增加，与报告期内收入增长基本一致。公告显示，百奥赛图为临床前研究服务公司，主营业务为新型抗体药物的研发和创收，属于临床前研究服务行业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023032720145282be6044&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023032720145282be6044&s=b","is_publish_highlight":false},{"id":"2322443494","title":"百奥赛图-B(02315)发布年度业绩，股东应占亏损6.02亿元 同比增加10.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2322443494","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2322443494?lang=zh_CN&edition=full","pubTime":"2023-03-27 18:23","pubTimestamp":1679912626,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥赛图-B 发布截至2022年12月31日止年度业绩，该集团取得收益人民币5.34亿元，同比增加50.6%;公司权益股东应占亏损6.02亿元，同比增加10.33%;每股亏损1.58元。截至2022年12月31日，公司的研发团队已发现及/或研发11种候选药物作为目前的产品管线。截至2022年12月31日，公司三个服务中心有约550名研发人员从事临床前研究服务。截至2022年12月31日止年度，核心产品的研发费用为1.05亿元，约占同期研发费用的15.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/899388.html","is_publish_highlight":false},{"id":"2322644439","title":"百奥赛图-B(02315.HK)公布业绩：2022年收益5.34亿元 同比增长50.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2322644439","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2322644439?lang=zh_CN&edition=full","pubTime":"2023-03-27 18:23","pubTimestamp":1679912624,"startTime":"0","endTime":"0","summary":"格隆汇3月27日丨百奥赛图-B发布公告，截至2022年12月31日止年度，收益为人民币5.34亿元，同比增长50.6%；毛利为人民币3.92亿元，同比增长58.3%。截至2022年12月31日，集团三个服务中心有约550名研发人员从事临床前研究服务。截至2021年及2022年12月31日止年度，集团的研发费用分别为人民币5.59亿元及人民币6.99亿元。截至2022年12月31日止年度，核心产品的研发费用为人民币1.05亿元，约占同期研发费用的15.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230327182353841ec628&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230327182353841ec628&s=b","is_publish_highlight":false},{"id":"2319890258","title":"百奥赛图-B(02315.HK)3月27日董事会考虑及批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2319890258","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2319890258?lang=zh_CN&edition=full","pubTime":"2023-03-15 17:28","pubTimestamp":1678872483,"startTime":"0","endTime":"0","summary":"格隆汇3月15日丨百奥赛图-B(02315.HK)宣布，董事会会议将于2023年3月27日(星期一)举行，藉以(其中包括)(i)考虑及批准公司及其附属公司截至2022年12月31日止年度的年度业绩及其发布，以及(ii)考虑派发末期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230315173002826b2c0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230315173002826b2c0d&s=b","is_publish_highlight":false},{"id":"2318727695","title":"招银国际：维持百奥赛图-B买入评级 目标价40.51港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2318727695","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2318727695?lang=zh_CN&edition=full","pubTime":"2023-03-10 14:58","pubTimestamp":1678431536,"startTime":"0","endTime":"0","summary":"招银国际发布研究报告称，维持百奥赛图-B“买入”评级，看好其全人源小鼠平台的优势，认为“千鼠万抗”下的分子将实现持续对外授权，目标价40.51港元。截至2022年6月末，公司“千鼠万抗”项目已完成28个分子的合作及对外授权，该项目将在2023年及之后带来持续的现金流。近期，公司将YH008中国权益转让给微芯生物，交易金额最高达5.96亿元。　　该行预计，公司2022年全年收入将同比增长50%至5.3亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2023-03-10/doc-imykkkfw9765058.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2023-03-10/doc-imykkkfw9765058.shtml","is_publish_highlight":false},{"id":"2317947713","title":"百奥赛图-B(02315)与杨森达成RenLite®非独家授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2317947713","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2317947713?lang=zh_CN&edition=full","pubTime":"2023-03-08 16:34","pubTimestamp":1678264464,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥赛图-B 发布公告，该公司与杨森制药公司下属的杨森生物技术公司(杨森)，达成非独家授权协议。RenLite是百奥赛图全人抗体小鼠RenMice家族中的一员。截至2022年6月30日，百奥赛图自主研发的全人抗体RenMice平台已与全球16家生物制药公司达成授权使用协议，包括德国默克、Xencor、百济神州、信达生物等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/888512.html","is_publish_highlight":false},{"id":"2317703661","title":"百奥赛图(02315.HK)建议发行A股科创板上市  净筹近19亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2317703661","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2317703661?lang=zh_CN&edition=full","pubTime":"2023-03-07 00:38","pubTimestamp":1678120680,"startTime":"0","endTime":"0","summary":"百奥赛图－Ｂ(02315.HK) 公布，建议发行不多于9,984.96万股A股，并向上海证券交易所申请批准A股在科创板上市。预计集资净额18.93亿人民币，将用于药物早期研发服务平台建设项目、抗体药物研发及评价项目、临床前及临床研发项目及补充流动资金。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2023-03-06 16:25。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20221007162300628_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20221007162300628_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1249602/latest-news/HK6","is_publish_highlight":false},{"id":"2317272781","title":"百奥赛图-B(02315)建议发行不多于9984.96万股A股并在科创板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2317272781","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2317272781?lang=zh_CN&edition=full","pubTime":"2023-03-06 20:37","pubTimestamp":1678106246,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥赛图-B(02315)发布公告，于2023年3月6日举行的董事会会议上，公司建议向中国相关监管机构申请配发及发行不多于9984.96万股A股，以及向上海证券交易所申请批准A股在科创板上市及买卖。A股发行所得款项将用于药物早期研发服务平台建设项目、抗体药物研发及评价项目、临床前及临床研发项目及补充流动资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/887518.html","is_publish_highlight":false},{"id":"2317115393","title":"百奥赛图－Ｂ(02315)股价下跌5.047%，现价港币$25.4","url":"https://stock-news.laohu8.com/highlight/detail?id=2317115393","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2317115393?lang=zh_CN&edition=full","pubTime":"2023-03-06 10:25","pubTimestamp":1678069500,"startTime":"0","endTime":"0","summary":"[下跌股]百奥赛图－Ｂ(02315) 股价在上午10:25比前收市价下跌5.047%，现股价为港币$25.4。至目前为止，今日最高价为$27.35，而最低价为$25.4。总成交量为3.45万股，总成交金额为港币$90.078万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD230306907/aamm-all-category","is_publish_highlight":false},{"id":"2314056901","title":"百奥赛图(02315.HK)YH008双特异性抗体达成授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2314056901","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2314056901?lang=zh_CN&edition=full","pubTime":"2023-02-28 00:32","pubTimestamp":1677515520,"startTime":"0","endTime":"0","summary":"百奥赛图－Ｂ(02315.HK) 公布，全资子公司祐和医药与微芯生物(688321.SH) 的控股公司微芯新域，就其YH008双特异性抗体达成在大中华局(内地以及港澳台)的临床开发及商业化授权协议。据此，微芯新域将支付祐和医药4,000万人民币首付款，不超过3.6亿人民币的潜在研发里程碑付款，不超过1.96亿人民币的潜在销售里程碑付款，以及销售净额的分级特许权使用费。(de/d)(港股报价延迟最少十五分钟。) (A股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180321105506149_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180321105506149_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1247882/latest-news/HK6","is_publish_highlight":false},{"id":"2314537237","title":"微芯生物(688321.SH)附属与百奥赛图(02315)子公司签署关于YH008的独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2314537237","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2314537237?lang=zh_CN&edition=full","pubTime":"2023-02-27 18:48","pubTimestamp":1677494932,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物 公告，公司控股子公司成都微芯新域生物技术有限公司与百奥赛图(北京)医药科技股份有限公司全资子公司祐和医药科技(北京)有限公司就双特异抗体新药YH008签署《独家许可协议》，微芯新域将获得祐和医药YH008在大中华区的研发、生产和商业化的独占许可权益。公告显示，YH008是一款百奥赛图自主研发、同类首创、专有的用于肿瘤免疫治疗的双特异性抗体。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/883393.html","is_publish_highlight":false},{"id":"2314344015","title":"百奥赛图-B(02315)与微芯生物(688321.SH)控股公司微芯新域就YH008双特异性抗体达成大中华区授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2314344015","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2314344015?lang=zh_CN&edition=full","pubTime":"2023-02-27 18:08","pubTimestamp":1677492511,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥赛图-B(02315)发布公告，公司全资子公司祐和医药科技(北京)有限公司就其YH008双特异性抗体与深圳微芯生物科技股份有限公司(688321.SH)的公司的控股公司成都微芯新域生物技术有限公司，达成在中国大陆、中国香港、中国澳门和中国台湾地区(大中华区)的临床开发及商业化授权协议。根据授权协议，微芯新域将支付祐和医药人民币4000万元(单位下同)首付款，不超过3.60亿元的潜在研发里程碑付款，不超过1.96亿元的潜在销售里程碑付款，以及销售净额的分级特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/883317.html","is_publish_highlight":false},{"id":"2313722269","title":"百奥赛图(02315.HK)拟开发针对100+靶点全人治疗性纳米抗体","url":"https://stock-news.laohu8.com/highlight/detail?id=2313722269","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2313722269?lang=zh_CN&edition=full","pubTime":"2023-02-21 11:32","pubTimestamp":1676950320,"startTime":"0","endTime":"0","summary":"百奥赛图宣布启动“Nano 100计划”，以开发针对100+靶点的全人治疗性纳米抗体，包括肿瘤相关抗原、GPCRs、免疫检查点、细胞因子、神经因子等。该计划的目标是依托百奥赛图自主研发的全人纳米抗体小鼠RenNano及高通量体外体内筛选平台，规模化开发全人纳米抗体药物。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230221113639233_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230221113639233_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1246403/latest-news/HK6","is_publish_highlight":false},{"id":"2313428167","title":"百奥赛图宣布启动“Nano 100计划”，开发针对100+靶点的全人治疗性纳米抗体","url":"https://stock-news.laohu8.com/highlight/detail?id=2313428167","media":"美国商业资讯","top":-1,"share":"https://www.laohu8.com/m/news/2313428167?lang=zh_CN&edition=full","pubTime":"2023-02-21 00:00","pubTimestamp":1676908800,"startTime":"0","endTime":"0","summary":"已有的体外、体内实验表明，这些RenNano来源的抗体具有良好的生物学功能。基于RenNano小鼠在全人纳米抗体发现的优势，百奥赛图发起了“Nano 100计划”，针对100+靶点开发全人治疗性纳米抗体，包括肿瘤相关抗原、GPCRs、免疫检查点、细胞因子、神经因子等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023022108010683503c74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023022108010683503c74&s=b","is_publish_highlight":false},{"id":"2309555234","title":"东吴证券：合成生物学具有强壁垒属性 多因素推动行业高速发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2309555234","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2309555234?lang=zh_CN&edition=full","pubTime":"2023-02-08 09:32","pubTimestamp":1675819972,"startTime":"0","endTime":"0","summary":"▍东吴证券主要观点如下：合成生物学造通过对生物体进行有目标地设计、改造乃至重新合成，可以实现以合成生物为工具进行物质加工与合成的新型生产制造方式。合成生物学由于存在多学科交叉、对技术、成本控制、研发人员要求高，具有强壁垒属性。合成生物学在底层技术的进步和成本下降下，已取得了长足的进步，同时政府政策对于产业的鼓励不言而喻，在资本推动下合成生物学行业迎来了高速发展的时机。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/872919.html","is_publish_highlight":false},{"id":"2308019961","title":"百奥赛图-B盘中异动 股价大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2308019961","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2308019961?lang=zh_CN&edition=full","pubTime":"2023-02-02 15:09","pubTimestamp":1675321750,"startTime":"0","endTime":"0","summary":"2023年02月02日下午盘15时09分，百奥赛图-B股票出现异动，股价快速上涨5.12%。截至发稿，该股报26.650港元/股，成交量15.5万股，换手率0.14%，振幅5.72%。百奥赛图-B股票所在的生物技术行业中，整体涨幅为1.45%。百奥赛图-B公司简介：北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023020215091082b3e3c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023020215091082b3e3c2&s=b","is_publish_highlight":false},{"id":"2301407016","title":"百奥赛图-B盘中异动 早盘股价大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2301407016","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2301407016?lang=zh_CN&edition=full","pubTime":"2023-01-05 09:30","pubTimestamp":1672882241,"startTime":"0","endTime":"0","summary":"2023年01月05日早盘09时30分，百奥赛图-B股票出现波动，股价大幅上涨5.09%。百奥赛图-B股票所在的生物技术行业中，整体涨幅为1.13%。百奥赛图许可翰森制药其所选定的全人抗体分子，用于全球范围内药物的开发、生产及商业化。未来，百奥赛图将继续携手全球合作伙伴，持续产出众多抗体药物，更好地惠及患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023010509304182aed6eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023010509304182aed6eb&s=b","is_publish_highlight":false},{"id":"2300145413","title":"【港股通】翰森制药(03692)涨6.75% 与百奥赛图签署抗体药物分子合作许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2300145413","media":"金吾资讯","top":-1,"share":"https://www.laohu8.com/m/news/2300145413?lang=zh_CN&edition=full","pubTime":"2023-01-04 10:54","pubTimestamp":1672800890,"startTime":"0","endTime":"0","summary":"翰森制药(03692)股价走势向好，连升两日，最新报16.12港元，涨6.75%，成交额5359万港元。据报道，百奥赛图宣布与翰森制药签署抗体药物分子合作、转让和独家许可协议。百奥赛图许可翰森制药其所选定的全人抗体分子，用于全球范围内药物的开发、生产及商业化。根据协议，百奥赛图将收到首付款、不同开发阶段和商业化的里程碑付款，累计可达数亿元；未来还将获得基于产品的个位数净销售额分成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230104105511824a78a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230104105511824a78a4&s=b","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":-0.004},{"period":"3month","weight":-0.0137},{"period":"6month","weight":-0.0526},{"period":"1year","weight":-0.0008},{"period":"ytd","weight":-0.0175}],"websiteUrl":"http://www.bbctg.com.cn","compareEarnings":[{"period":"1week","weight":0.0298},{"period":"1month","weight":-0.0221},{"period":"3month","weight":-0.0013},{"period":"6month","weight":0.1343},{"period":"1year","weight":-0.0858},{"period":"ytd","weight":-0.0108}],"name":"百奥赛图-B","description":"北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。该公司运营两个业务部门。药物开发业务部门主要从事肿瘤学和自身免疫性疾病治疗的研发，及抗体开发业务。临床前研究服务部门主要从事基因编辑、临床前药理药效评估及模式动物销售。","exchange":"SEHK","nameEN":"BIOCYTOGEN-B","compareStock":{"symbol":"HSI","name":"恒生指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.12.1","shortVersion":"4.12.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥赛图-B(02315)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥赛图-B(02315)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥赛图-B,02315,百奥赛图-B股票,百奥赛图-B股票老虎,百奥赛图-B股票老虎国际,百奥赛图-B行情,百奥赛图-B股票行情,百奥赛图-B股价,百奥赛图-B股市,百奥赛图-B股票价格,百奥赛图-B股票交易,百奥赛图-B股票购买,百奥赛图-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥赛图-B(02315)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥赛图-B(02315)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}